Liying Zhang

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:301-7. 2008
  2. ncbi A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Mol Diagn 11:176-81. 2009
  3. ncbi NF-kappaB regulates androgen receptor expression and prostate cancer growth
    Liying Zhang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 36, New York, NY 10065, USA
    Am J Pathol 175:489-99. 2009
  4. ncbi BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, P O Box 36, New York, NY 10065, USA
    Breast Cancer Res Treat 130:1051-6. 2011
  5. ncbi cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mutat Res 663:84-9. 2009
  6. ncbi Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
    Jeff Holzbeierlein
    Department of Urology, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 164:217-27. 2004
  7. ncbi Germline PALB2 mutation analysis in breast-pancreas cancer families
    Zsofia K Stadler
    Clinical Genetics and Gastroenterology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Med Genet 48:523-5. 2011
  8. ncbi Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature
    Yevgeniy Karamurzin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hum Pathol 43:1677-87. 2012

Collaborators

Detail Information

Publications8

  1. ncbi Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:301-7. 2008
    ..MSI has been used and will continue to prevail as the primary screening tool for identifying HNPCC patients...
  2. ncbi A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Mol Diagn 11:176-81. 2009
    ..We show that pyrosequencing is a rapid and reliable method that serves as an excellent platform for BRCA founder mutation analysis, especially when only paraffin-embedded tissues are available...
  3. ncbi NF-kappaB regulates androgen receptor expression and prostate cancer growth
    Liying Zhang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 36, New York, NY 10065, USA
    Am J Pathol 175:489-99. 2009
    ..In addition, levels of both NF-kappaB and AR were strongly correlated in human prostate cancer. Our data suggest that NF-kappaB can regulate AR expression in prostate cancer and that NF-kappaB inhibitors may have therapeutic potential...
  4. ncbi BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, P O Box 36, New York, NY 10065, USA
    Breast Cancer Res Treat 130:1051-6. 2011
    ..Analysis of a tumor specimen indicates loss of heterozygosity. These results support the conclusion that BRCA1 331G > A (R71K) is a deleterious mutation...
  5. ncbi cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation
    Liying Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mutat Res 663:84-9. 2009
    ..These results support the conclusion that BRCA2 IVS4-12del5 is a deleterious mutation. This study will shed light on the reclassification of intronic variants that do not disrupt the 5' and 3' splice sites (the GU-AG rule)...
  6. ncbi Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
    Jeff Holzbeierlein
    Department of Urology, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Am J Pathol 164:217-27. 2004
    ..The specific pathways of reactivation provide opportunities for classification of resistant tumors and targeted therapies...
  7. ncbi Germline PALB2 mutation analysis in breast-pancreas cancer families
    Zsofia K Stadler
    Clinical Genetics and Gastroenterology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Med Genet 48:523-5. 2011
    ..Germline mutations in the PALB2 gene have been implicated in both breast cancer and pancreatic cancer susceptibility. The extent to which PALB2 mutations account for cancer susceptibility in breast-pancreas cancer families is unknown...
  8. ncbi Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature
    Yevgeniy Karamurzin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Hum Pathol 43:1677-87. 2012
    ..As yet, however, there are no data to support the inclusion of these tumors into general screening guidelines for detecting Lynch syndrome, nor are there data to warrant surveillance for these tumors in patients with Lynch syndrome...